Edwin O. W. Bredewold
Edwin O. W. Bredewold has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Anders Hartmann
Department of Transplantation Medicine, University of Oslo
3 shared publicationsAnnette Bruchfeld
Department of Health, Medicine and Caring Sciences, Linköping University
3 shared publicationsHans Furuland
Department of Medical Sciences, Uppsala Universitet
3 shared publicationsInga Soveri
Department of Medical Sciences, Uppsala Universitet
3 shared publicationsJoe Chan
Department of Nephrology, Akerhus University Hospital
3 shared publicationsKarin Skov
Department of Renal Medicine, Aarhus University Hospital
3 shared publications
Latest Publications
- Open Access
- 11 June 2026
- Published by Frontiers Media SA in Frontiers in Transplantation
- Vol. 5, 1812847
An exploration of markers of microvascular dysfunction in kidney transplant recipients randomized to belatacept: no clinical impact of CNIs on endothelial function
Introduction: Side effects of calcineurin inhibitors (CNI) comprise hypertension, diabetes and nephrotoxicity, and endothelial dysfunction (ED) has often been implicated. Belatacept, a co-stimulation blocker, may offer a more favourable vascular profile. Methods: We investigated markers of endothelial function in blood samples from kidney transplant recipients (KTR) that were converted from CNI to belatacept. We assessed established markers of ED including soluble thrombomodulin, P-selectin and angiopoietin 1 and 2. In addition, we assessed expression levels of microRNAs (miRNAs), which have been identified as discriminative markers for ED, rejection and renal fibrosis in the setting of transplantation. Lastly, we used patient samples and CNI-dilution series in a validated model of ED in which changes in morphological characteristics of endothelial cells were evaluated. Results: Unexpectedly, we found no differences in our assays between both groups. We did observe dose-related effects of CNI on endothelial cell (EC) morphology upon direct exposure of EC to tacrolimus and ciclosporin A, but a similar effect was not seen when plasma samples of KTR who were converted to belatacept were compared with samples from KTR on CNI's. Discussion: These data suggest that CNI-side-effects bundled under the term “CNI-toxicity” are not derived from a significant clinical effect of CNI on endothelial function.
- 11 June 2026
- Published by Frontiers Media SA in Frontiers in Transplantation
- Vol. 5, 1812847
Open AccessAn exploration of markers of microvascular dysfunction in kidney transplant recipients randomized to belatacept: no clinical impact of CNIs on endothelial function
Introduction: Side effects of calcineurin inhibitors (CNI) comprise hypertension, diabetes and nephrotoxicity, and endothelial dysfunction (ED) has often been implicated. Belatacept, a co-stimulation blocker, may offer a more favourable vascular profile. Methods: We investigated markers of endothelial function in blood samples from kidney transplant recipients (KTR) that were converted from CNI to belatacept. We assessed established markers of ED including soluble thrombomodulin, P-selectin and angiopoietin 1 and 2. In addition, we assessed expression levels of microRNAs (miRNAs), which have been identified as discriminative markers for ED, rejection and renal fibrosis in the setting of transplantation. Lastly, we used patient samples and CNI-dilution series in a validated model of ED in which changes in morphological characteristics of endothelial cells were evaluated. Results: Unexpectedly, we found no differences in our assays between both groups. We did observe dose-related effects of CNI on endothelial cell (EC) morphology upon direct exposure of EC to tacrolimus and ciclosporin A, but a similar effect was not seen when plasma samples of KTR who were converted to belatacept were compared with samples from KTR on CNI's. Discussion: These data suggest that CNI-side-effects bundled under the term “CNI-toxicity” are not derived from a significant clinical effect of CNI on endothelial function.
- Open Access
- 4 September 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (9) , e29905
Attenuation of Torque teno viral load over time in kidney transplantation recipients treated with calcineurin inhibitors is mitigated after conversion to belatacept
Torque Teno Virus (TTV) is a non‐pathogenic anellovirus, highly prevalent in healthy populations. Variations in its viral load have been associated with states of diminished immunity, as occurs after organ transplantation. It is hypothesized that TTV‐load might be used as a diagnostic tool to guide prescription and dosing of immunosuppressive drugs. Not much is known about the effects of combined immunosuppressive drugs on TTV replication in renal transplantation. Belatacept was introduced to counter side‐effects of calcineurin inhibitors (CNI). It was never widely adopted, mainly because its association with increased risk of rejection. To investigate the differential effects of a regimen based on calcineurin inhibitors versus belatacept on TTV‐loads, we measured TTV‐levels in 105 patients from two randomized controlled trials in kidney transplant recipients (KTRs). We observed that time after transplantation was inversely related to TTV‐levels of patients that remained on a CNI‐containing regime, whereas this decline over time was diminished after conversion to belatacept. In addition, a correlation with tacrolimus‐trough levels and age were found. Our study is the first report on the impact of conversion from CNI to belatacept on TTV‐levels in KTR. In conclusion, the time‐related decline in TTV‐levels is mitigated after conversion from CNI to belatacept.
- 4 September 2024
- Published by Wiley in Journal of Medical Virology
- Vol. 96 (9) , e29905
Open AccessAttenuation of Torque teno viral load over time in kidney transplantation recipients treated with calcineurin inhibitors is mitigated after conversion to belatacept
Torque Teno Virus (TTV) is a non‐pathogenic anellovirus, highly prevalent in healthy populations. Variations in its viral load have been associated with states of diminished immunity, as occurs after organ transplantation. It is hypothesized that TTV‐load might be used as a diagnostic tool to guide prescription and dosing of immunosuppressive drugs. Not much is known about the effects of combined immunosuppressive drugs on TTV replication in renal transplantation. Belatacept was introduced to counter side‐effects of calcineurin inhibitors (CNI). It was never widely adopted, mainly because its association with increased risk of rejection. To investigate the differential effects of a regimen based on calcineurin inhibitors versus belatacept on TTV‐loads, we measured TTV‐levels in 105 patients from two randomized controlled trials in kidney transplant recipients (KTRs). We observed that time after transplantation was inversely related to TTV‐levels of patients that remained on a CNI‐containing regime, whereas this decline over time was diminished after conversion to belatacept. In addition, a correlation with tacrolimus‐trough levels and age were found. Our study is the first report on the impact of conversion from CNI to belatacept on TTV‐levels in KTR. In conclusion, the time‐related decline in TTV‐levels is mitigated after conversion from CNI to belatacept.
- Open Access
- 8 January 2024
- Published by Elsevier in Transplant Immunology
- Vol. 82, 101976
Conversion from calcineurin inhibitors to belatacept-based immunosuppressive therapy skews terminal proliferation of non-classical monocytes and lowers lymphocyte counts
- 8 January 2024
- Published by Elsevier in Transplant Immunology
- Vol. 82, 101976
Open AccessConversion from calcineurin inhibitors to belatacept-based immunosuppressive therapy skews terminal proliferation of non-classical monocytes and lowers lymphocyte counts
- Open Access
- 18 November 2022
- Published by Elsevier in Kidney Medicine
- Vol. 5 (1) , 100574
Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial
- 18 November 2022
- Published by Elsevier in Kidney Medicine
- Vol. 5 (1) , 100574
Open AccessCardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial
- Open Access
- 3 February 2022
- Published by Springer Nature in Research Square
Calculated cardiovascular risk after conversion from calcineurin inhibitor to belatacept in kidney transplant recipients: A randomized controlled trial
In renal transplant recipients (RTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)-based regimens. The aim of this randomized, multi-national trial was to compare calculated CV risk between belatacept and CNI (predominantly tacrolimus) treatments using a valdidated model developed for RTRs. From 9 transplant centers, RTRs from 3 to 60 months post-transplantation were recruited to either continue treatment with a CNI-based regimen or switch to belatacept. We compared the change in estimated 7-year risk of major adverse cardiovascular events (MACE) and all-cause mortality after 12 months of treatment. In the 105 RTRs randomized, we found no differences between the treatment groups in predicted risk for MACE or mortality. Diastolic blood pressure was lower after belatacept treatment compared with CNI. The mean changes in traditional CV risk factors, including renal transplant function, were otherwise similar in both treatment groups. The belatacept group had four acute rejection episodes; two were severe rejections, of which one led to graft loss. In conclusion, we found no effects on calculated CV risk by switching to belatacept treatment.
- 3 February 2022
- Published by Springer Nature in Research Square
Open AccessCalculated cardiovascular risk after conversion from calcineurin inhibitor to belatacept in kidney transplant recipients: A randomized controlled trial
In renal transplant recipients (RTRs), a belatacept-based immunosuppressive regimen is associated with beneficial effects on cardiovascular (CV) risk factors compared with calcineurin inhibitor (CNI)-based regimens. The aim of this randomized, multi-national trial was to compare calculated CV risk between belatacept and CNI (predominantly tacrolimus) treatments using a valdidated model developed for RTRs. From 9 transplant centers, RTRs from 3 to 60 months post-transplantation were recruited to either continue treatment with a CNI-based regimen or switch to belatacept. We compared the change in estimated 7-year risk of major adverse cardiovascular events (MACE) and all-cause mortality after 12 months of treatment. In the 105 RTRs randomized, we found no differences between the treatment groups in predicted risk for MACE or mortality. Diastolic blood pressure was lower after belatacept treatment compared with CNI. The mean changes in traditional CV risk factors, including renal transplant function, were otherwise similar in both treatment groups. The belatacept group had four acute rejection episodes; two were severe rejections, of which one led to graft loss. In conclusion, we found no effects on calculated CV risk by switching to belatacept treatment.
- Open Access
- 2 September 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (17) , 6364
Prediction Power on Cardiovascular Disease of Neuroimmune Guidance Cues Expression by Peripheral Blood Monocytes Determined by Machine-Learning Methods
Atherosclerosis is the underlying pathology in a major part of cardiovascular disease, the leading cause of mortality in developed countries. The infiltration of monocytes into the vessel walls of large arteries is a key denominator of atherogenesis, making monocytes accountable for the development of atherosclerosis. With the development of high-throughput transcriptome profiling platforms and cytometric methods for circulating cells, it is now feasible to study in-depth the predicted functional change of circulating monocytes reflected by changes of gene expression in certain pathways and correlate the changes to disease outcome. Neuroimmune guidance cues comprise a group of circulating- and cell membrane-associated signaling proteins that are progressively involved in monocyte functions. Here, we employed the CIRCULATING CELLS study cohort to classify cardiovascular disease patients and healthy individuals in relation to their expression of neuroimmune guidance cues in circulating monocytes. To cope with the complexity of human datasets featured by noisy data, nonlinearity and multidimensionality, we assessed various machine-learning methods. Of these, the linear discriminant analysis, Naïve Bayesian model and stochastic gradient boost model yielded perfect or near-perfect sensibility and specificity and revealed that expression levels of the neuroimmune guidance cues SEMA6B, SEMA6D and EPHA2 in circulating monocytes were of predictive values for cardiovascular disease outcome.
- 2 September 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (17) , 6364
Open AccessPrediction Power on Cardiovascular Disease of Neuroimmune Guidance Cues Expression by Peripheral Blood Monocytes Determined by Machine-Learning Methods
Atherosclerosis is the underlying pathology in a major part of cardiovascular disease, the leading cause of mortality in developed countries. The infiltration of monocytes into the vessel walls of large arteries is a key denominator of atherogenesis, making monocytes accountable for the development of atherosclerosis. With the development of high-throughput transcriptome profiling platforms and cytometric methods for circulating cells, it is now feasible to study in-depth the predicted functional change of circulating monocytes reflected by changes of gene expression in certain pathways and correlate the changes to disease outcome. Neuroimmune guidance cues comprise a group of circulating- and cell membrane-associated signaling proteins that are progressively involved in monocyte functions. Here, we employed the CIRCULATING CELLS study cohort to classify cardiovascular disease patients and healthy individuals in relation to their expression of neuroimmune guidance cues in circulating monocytes. To cope with the complexity of human datasets featured by noisy data, nonlinearity and multidimensionality, we assessed various machine-learning methods. Of these, the linear discriminant analysis, Naïve Bayesian model and stochastic gradient boost model yielded perfect or near-perfect sensibility and specificity and revealed that expression levels of the neuroimmune guidance cues SEMA6B, SEMA6D and EPHA2 in circulating monocytes were of predictive values for cardiovascular disease outcome.
- Open Access
- 14 April 2011
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 4 (3) , 170-172
A case of mononucleosis infectiosa presenting with cholemic nephrosis
A 38-year-old male was admitted with fever, progressive jaundice, cervical lymphadenopathy, hepatomegaly and acute oliguric renal failure. Epstein-Barr virus (EBV) infection was diagnosed by detection of EBV-DNA in plasma and confirmed by EBV seroconversion. Kidney biopsy revealed acute tubular necrosis and abundant casts, consisting of bilirubin pigment. With conservative treatment, the patient fully recovered from cholemic nephrosis, an uncommon condition, not described after EBV infection before.
- 14 April 2011
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 4 (3) , 170-172
Open AccessA case of mononucleosis infectiosa presenting with cholemic nephrosis
A 38-year-old male was admitted with fever, progressive jaundice, cervical lymphadenopathy, hepatomegaly and acute oliguric renal failure. Epstein-Barr virus (EBV) infection was diagnosed by detection of EBV-DNA in plasma and confirmed by EBV seroconversion. Kidney biopsy revealed acute tubular necrosis and abundant casts, consisting of bilirubin pigment. With conservative treatment, the patient fully recovered from cholemic nephrosis, an uncommon condition, not described after EBV infection before.